A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib for Patients with High Allelic Ratio
Sponsor: COG
Protocol number: AAML1031
Projected enrollment dates: December 2014 to November 2016
Official study title: A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib for Patients with High Allelic Ratio
ClinicalTrials.gov page:
http://www.clinicaltrials.gov/show/NCT01371981